LLY vs NVST

Eli Lilly exhibits a stark divergence between explosive growth and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company delivers exceptional ROE (101.16%) and massive YoY revenue growth (42.6%), it trades at a significant premium to both its Graham Number ($123.85) and growth-based intrinsic value ($678.2). The current valuation is driven by high expectations for its drug pipeline, but the low deterministic health score and bearish technical trend suggest a period of consolidation or risk. Overall, it is a high-performance growth engine with concerning balance sheet efficiency metrics.

NVST presents a complex profile with a stable Piotroski F-Score of 4/9 and a significant valuation gap, as the current price of $25.94 far exceeds the Graham Number ($10.93) and Intrinsic Value ($8.26). While the company shows strong short-term price momentum (+61.3% 1Y) and a highly attractive Forward P/E of 16.64, its trailing P/E of 92.64 and razor-thin profit margin of 1.73% indicate a precarious transition period. The bullish analyst consensus is countered by bearish insider sentiment and a 0/100 technical trend, suggesting the market is pricing in a recovery that has not yet fully materialized in the fundamentals.